Penumbra (PEN) Fundamentals 2026 — P/E 72.3x, Revenue Analysis | SniperIQ
Penumbra (PEN) is a US-listed Healthcare company in Medical - Devices with a market capitalization of
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Penumbra's market cap?
Penumbra (PEN) has a market capitalization of approximately
What is Penumbra's P/E ratio?
Penumbra's trailing twelve-month P/E ratio is 72.3x, with a price-to-book (P/B) of 8.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Penumbra?
Penumbra runs a net profit margin of 11.8%, a gross margin of 67.4%, and an operating margin of 12.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Penumbra generate?
Penumbra reported revenue of
Does Penumbra pay a dividend?
Penumbra does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Penumbra financially healthy?
Penumbra carries a debt-to-equity ratio of 0.15x and a current ratio of 6.02x, with a market beta of 0.70. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Penumbra a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Penumbra (PEN) the key facts are: market cap
Track Penumbra's full fundamentals live
Get Penumbra's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.